Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).

Abulkhair, O.Uslu, R.Sezgin, C.Bueyuekberber, S.Darwish, T.Isikdogan, A.Gumus, M.Dane, F.Sevinc, A.Halawani, H.Uncu, D.Marrero, N.Tobler, J.Soares, C.Landis, S.Moraes, E.Gidekel, R.Santillana, S.Nunez, P.Cagnolati, S.Rodriguez, J. G.2019-10-272019-10-2720120008-54721538-7445https://doi.org/10.1158/0008-5472.SABCS12-OT1-1-08https://hdl.handle.net/11454/48272en10.1158/0008-5472.SABCS12-OT1-1-08info:eu-repo/semantics/closedAccessClinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).Conference Object72WOS:000209704900083Q1